Guo Ma

National Key Laboratory Of Advanced Drug Formulations For Overcoming Delivery Barriers, Fudan.edu.cn
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

CCDC97 is a Promising Predictor in Cancer Diagnosis: A Pan Cancer Analysis.

CCDC97 is a Promising Predictor in Cancer Diagnosis: A Pan Cancer Analysis.

Journal: Analytical cellular pathology (Amsterdam)

Published: October 09, 2025

Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.

Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.

Journal: BMC medicine

Published: September 17, 2025

A new type of ultrasonic water alleviates constipation with favorable safety.

A new type of ultrasonic water alleviates constipation with favorable safety.

Journal: Frontiers in toxicology

Published: August 25, 2025

Mechanistic insights into metformin's anti-hyperuricemic effect: Targeting PPP/DNPB/XOD-mediated purine pathway, purinosome assembly, and gut microbiota homostasis in rats.

Mechanistic insights into metformin's anti-hyperuricemic effect: Targeting PPP/DNPB/XOD-mediated purine pathway, purinosome assembly, and gut microbiota homostasis in rats.

Journal: Chemico-biological interactions

Published: August 19, 2025

Comparison and Evaluation of Efficacy and Safety of Sitagliptin and Linagliptin in Adults With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.

Comparison and Evaluation of Efficacy and Safety of Sitagliptin and Linagliptin in Adults With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.

Journal: Journal of evidence-based medicine

Published: August 13, 2025

Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling.

Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: July 28, 2025

Evaluation and comparison of efficacy and safety of mitochondrial modulator (Imeglimin) and DPP-4 inhibitors in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.

Evaluation and comparison of efficacy and safety of mitochondrial modulator (Imeglimin) and DPP-4 inhibitors in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.

Journal: Journal of endocrinological investigation

Published: March 28, 2025

Targeting hematopoietic progenitor kinase 1 (HPK1) for tumor immunotherapy: advances in small molecule inhibitors.

Targeting hematopoietic progenitor kinase 1 (HPK1) for tumor immunotherapy: advances in small molecule inhibitors.

Journal: Biochemical pharmacology

Published: March 16, 2025

Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis.

Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis.

Journal: BMJ open

Published: February 26, 2025

Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis.

Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis.

Journal: Current therapeutic research, clinical and experimental

Published: February 12, 2025

Gastrointestinal absorption and its regulation of hawthorn leaves flavonoids.

Gastrointestinal absorption and its regulation of hawthorn leaves flavonoids.

Journal: Scientific reports

Published: September 14, 2024

Editorial: Pharmacokinetic-pharmacodynamic model of drugs and their pharmacokinetic differences between normal and disease states.

Editorial: Pharmacokinetic-pharmacodynamic model of drugs and their pharmacokinetic differences between normal and disease states.

Journal: Frontiers in pharmacology

Published: June 18, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026